FLPIM
VRTX icon

F.L. Putnam Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

F.L. Putnam Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Buy
40,116
+618
+2% +$274K 0.24% 81
2026
Q1 		$17.6M Buy
39,498
+2,707
+7% +$1.26M 0.26% 73
2025
Q4 		$16.7M Buy
36,791
+2,115
+6% +$912K 0.24% 75
2025
Q3 		$13.6M Sell
34,676
-3,065
-8% -$1.28M 0.2% 93
2025
Q2 		$16.8M Buy
37,741
+1,245
+3% +$574K 0.29% 69
2025
Q1 		$17.7M Buy
36,496
+5,053
+16% +$2.35M 0.33% 65
2024
Q4 		$12.7M Buy
31,443
+22,141
+238% +$10.3M 0.23% 86
2024
Q3 		$4.33M Buy
9,302
+7,589
+443% +$3.65M 0.08% 176
2024
Q2 		$803K Buy
1,713
+267
+18% +$116K 0.02% 348
2024
Q1 		$604K Buy
1,446
+66
+5% +$27.9K 0.01% 313
2023
Q4 		$562K Buy
1,380
+16
+1% +$5.91K 0.01% 318
2023
Q3 		$474K Buy
1,364
+10
+0.7% +$3.5K 0.01% 343
2023
Q2 		$476K Buy
1,354
+149
+12% +$50.2K 0.01% 357
2023
Q1 		$380K Buy
1,205
+128
+12% +$38.4K 0.01% 336
2022
Q4 		$311K Buy
1,077
+150
+16% +$45.7K 0.01% 343
2022
Q3 		$268K Sell
927
-26
-3% -$7.48K 0.01% 350
2022
Q2 		$269K Sell
953
-7
-0.7% -$1.87K 0.01% 353
2022
Q1 		$251K Buy
960
+23
+2% +$5.46K 0.01% 369
2021
Q4 		$206K Buy
+937
New +$182K 0.01% 397
2021
Q2 		– Sell
-949
Closed -$204K – 417
2021
Q1 		$204K Sell
949
-63
-6% -$13.8K 0.01% 355
2020
Q4 		$239K Sell
1,012
-17
-2% -$3.9K 0.01% 296
2020
Q3 		$280K Hold
1,029
– – 0.02% 251
2020
Q2 		$299K Buy
1,029
+1
+0.1% +$271 0.02% 253
2020
Q1 		$245K Buy
+1,028
New +$236K 0.02% 250

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

F.L. Putnam Investment Management's VRTX Position: Q2 2026 in Review

F.L. Putnam Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q2 2026, buying an estimated $274K and bringing the position to 40,116 shares worth $19.9M. The position accounts for 0.24% of the portfolio, ranked #81.

F.L. Putnam Investment Management first reported a position in VRTX in Q1 2020 and has held it in 24 quarters since. 1,091 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • F.L. Putnam Investment Management held 40,116 shares of Vertex Pharmaceuticals worth $19.9M as of Q2 2026.
  • F.L. Putnam Investment Management bought 618 Vertex Pharmaceuticals shares in Q2 2026, an estimated $274K.
  • Vertex Pharmaceuticals made up 0.24% of F.L. Putnam Investment Management's portfolio in Q2 2026, its #81 holding.
  • F.L. Putnam Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 24 quarters since.
  • 1,091 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on F.L. Putnam Investment Management's 13F filing for Q2 2026, filed 6 Aug 2026.